First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes

Background: The objective of this study was to assess the safety and effectiveness of the first commercial configuration of a tubeless automated insulin delivery system, Omnipod(®) 5, in children (6–13.9 years) and adults (14–70 years) with type 1 diabetes (T1D) in an outpatient setting. Materials a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Technol Ther
Auteurs principaux: Forlenza, Gregory P., Buckingham, Bruce A., Brown, Sue A., Bode, Bruce W., Levy, Carol J., Criego, Amy B., Wadwa, R. Paul, Cobry, Erin C., Slover, Robert J., Messer, Laurel H., Berget, Cari, McCoy, Susan, Ekhlaspour, Laya, Kingman, Ryan S., Voelmle, Mary K., Boyd, Jennifer, O'Malley, Grenye, Grieme, Aimee, Kivilaid, Kaisa, Kleve, Krista, Dumais, Bonnie, Vienneau, Todd, Huyett, Lauren M., Lee, Joon Bok, O'Connor, Jason, Benjamin, Eric, Ly, Trang T.
Format: Artigo
Langue:Inglês
Publié: Mary Ann Liebert, Inc., publishers 2021
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215410/
https://ncbi.nlm.nih.gov/pubmed/33325779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2020.0546
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires